Document is current

Any future updates will be listed below

Frühe Therapie mit Empagliflozin von Vorteil

Crossref DOI link: https://doi.org/10.1007/s15027-021-3626-x

Published Online: 2022-02-22

Published Print: 2022-02

Update policy: https://doi.org/10.1007/springer_crossmark_policy

About CrossMark